ImmunoPrecise Antibodies/$IPA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
Ticker
$IPA
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
87
ISIN
CA45257F2008
Website
IPA Metrics
BasicAdvanced
$51M
-
-$1.19
0.38
-
Price and volume
Market cap
$51M
Beta
0.38
52-week high
$1.16
52-week low
$0.27
Average daily volume
3.3M
Financial strength
Current ratio
2.322
Quick ratio
1.99
Long term debt to equity
44.734
Total debt to equity
51.457
Interest coverage (TTM)
-50.46%
Profitability
EBITDA (TTM)
-9.166
Gross margin (TTM)
50.82%
Net profit margin (TTM)
-194.79%
Operating margin (TTM)
-61.61%
Effective tax rate (TTM)
8.69%
Revenue per employee (TTM)
$204,650
Management effectiveness
Return on assets (TTM)
-14.88%
Return on equity (TTM)
-124.75%
Valuation
Price to revenue (TTM)
1.815
Price to book
2.02
Price to tangible book (TTM)
3.15
Price to free cash flow (TTM)
-4.596
Free cash flow yield (TTM)
-21.76%
Free cash flow per share (TTM)
-24.15%
Growth
Revenue change (TTM)
1.34%
Earnings per share change (TTM)
201.55%
3-year revenue growth (CAGR)
8.09%
3-year earnings per share growth (CAGR)
22.34%
What the Analysts think about IPA
Analyst ratings (Buy, Hold, Sell) for ImmunoPrecise Antibodies stock.
IPA Financial Performance
Revenues and expenses
IPA Earnings Performance
Company profitability
IPA News
AllArticlesVideos
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
Business Wire·6 days ago
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
Business Wire·3 weeks ago
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunoPrecise Antibodies stock?
ImmunoPrecise Antibodies (IPA) has a market cap of $51M as of June 30, 2025.
What is the P/E ratio for ImmunoPrecise Antibodies stock?
The price to earnings (P/E) ratio for ImmunoPrecise Antibodies (IPA) stock is 0 as of June 30, 2025.
Does ImmunoPrecise Antibodies stock pay dividends?
No, ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next ImmunoPrecise Antibodies dividend payment date?
ImmunoPrecise Antibodies (IPA) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies (IPA) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.